Business Description
Maxigen Biotech Inc
NAICS : 325412
SIC : 2834
ISIN : TW0001783009
Description
Maxigen Biotech Inc specializes in the developing, manufacturing, and marketing of biomedical and cosmeceutical skincare products. It provides medical devices for orthopedic, ophthalmic, dental, and surgical applications. Skincare product categories include mask series, facial cleansing series, and body care series. The biomedical products segment is primarily engaged in the manufacturing and sales of collagen and bone materials, which forms the majority chunk of the revenue of the group. The consumer products segment is engaged in the manufacturing and sales of beauty care products.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 8651.64 | |||||
| Equity-to-Asset | 0.91 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 19.79 | |||||
| Beneish M-Score | 5.87 | |||||
| WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 7 | |||||
| 3-Year EBITDA Growth Rate | 21.8 | |||||
| 3-Year EPS without NRI Growth Rate | 33 | |||||
| 3-Year FCF Growth Rate | 28.5 | |||||
| 3-Year Book Growth Rate | 12.6 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 18.01 | |||||
| 9-Day RSI | 25.46 | |||||
| 14-Day RSI | 30.76 | |||||
| 6-1 Month Momentum % | -4.97 | |||||
| 12-1 Month Momentum % | -24.08 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.72 | |||||
| Quick Ratio | 4.07 | |||||
| Cash Ratio | 3.29 | |||||
| Days Inventory | 154.65 | |||||
| Days Sales Outstanding | 45.53 | |||||
| Days Payable | 66.44 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 1.14 | |||||
| Dividend Payout Ratio | 0.27 | |||||
| 3-Year Dividend Growth Rate | -9.5 | |||||
| Forward Dividend Yield % | 1.14 | |||||
| 5-Year Yield-on-Cost % | 1.14 | |||||
| 3-Year Average Share Buyback Ratio | -3.5 | |||||
| Shareholder Yield % | 1.32 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 68.17 | |||||
| Operating Margin % | 24.12 | |||||
| Net Margin % | 26.66 | |||||
| FCF Margin % | 23.91 | |||||
| ROE % | 12.4 | |||||
| ROA % | 11.07 | |||||
| ROIC % | 16.98 | |||||
| ROC (Joel Greenblatt) % | 43.42 | |||||
| ROCE % | 14.44 | |||||
| Years of Profitability over Past 10-Year | 7 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 22.72 | |||||
| PE Ratio without NRI | 22.69 | |||||
| Shiller PE Ratio | 76 | |||||
| Price-to-Owner-Earnings | 24.59 | |||||
| PEG Ratio | 1.12 | |||||
| PS Ratio | 6.04 | |||||
| PB Ratio | 2.75 | |||||
| Price-to-Tangible-Book | 2.75 | |||||
| Price-to-Free-Cash-Flow | 25.18 | |||||
| Price-to-Operating-Cash-Flow | 21.91 | |||||
| EV-to-EBIT | 17.13 | |||||
| EV-to-EBITDA | 14.98 | |||||
| EV-to-Revenue | 5.31 | |||||
| EV-to-FCF | 24.23 | |||||
| Price-to-Projected-FCF | 1.23 | |||||
| Price-to-Median-PS-Value | 1.09 | |||||
| Price-to-Peter-Lynch-Fair-Value | 1.03 | |||||
| Price-to-Graham-Number | 1.67 | |||||
| Price-to-Net-Current-Asset-Value | 7.67 | |||||
| Price-to-Net-Cash | 12.44 | |||||
| Earnings Yield (Greenblatt) % | 5.84 | |||||
| FCF Yield % | 3.96 | |||||
| Forward Rate of Return (Yacktman) % | 23.28 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Maxigen Biotech Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil NT$) | 622.115 | ||
| EPS (TTM) (NT$) | 1.85 | ||
| Beta | 0.4 | ||
| Volatility % | 29.15 | ||
| 14-Day RSI | 30.76 | ||
| 14-Day ATR (NT$) | 0.937808 | ||
| 20-Day SMA (NT$) | 45.135 | ||
| 12-1 Month Momentum % | -24.08 | ||
| 52-Week Range (NT$) | 41.8 - 71.428571 | ||
| Shares Outstanding (Mil) | 88.93 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Maxigen Biotech Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Maxigen Biotech Inc Stock Events
| Event | Date | Price(NT$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Maxigen Biotech Inc Frequently Asked Questions
What is Maxigen Biotech Inc(TPE:1783)'s stock price today?
The current price of TPE:1783 is NT$42.05. The 52 week high of TPE:1783 is NT$71.43 and 52 week low is NT$41.80.
When is next earnings date of Maxigen Biotech Inc(TPE:1783)?
The next earnings date of Maxigen Biotech Inc(TPE:1783) is .
Does Maxigen Biotech Inc(TPE:1783) pay dividends? If so, how much?
The Dividend Yield %  of Maxigen Biotech Inc(TPE:1783) is 1.14% (As of Today), Highest Dividend Payout Ratio of Maxigen Biotech Inc(TPE:1783) was 0.86. The lowest was 0.19. And the median was 0.59. The  Forward Dividend Yield % of Maxigen Biotech Inc(TPE:1783) is 1.14%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers